Figure 3.

Expression of IGF2BP3 across different hematological malignancies and subtypes of B-ALL. (A) IGF2BP3 expression in the Hemap data set in different hematological malignancies (n = 6832) [24,25]. (B) IGF2BP3 expression in different cytogenetic subtypes of B-ALL (n = 1304) in the Hemap data set [24,25]. (C) IGF2BP3 expression in different B-ALL subtypes of B-ALL in the PanALL study cohort (n = 1988) [26]. (D) Proliferation-associated “metagene” [33] expression in B-ALL in the Hemap and PanALL data sets (median as a cut-off for the IGF2BP3 expression groups). AILT—angioimmunoblastic T-cell lymphoma; ALCL—anaplastic large cell lymphoma; AML—acute myeloid leukemia; ATL—adult T-cell leukemia; B-ALL—B-cell lineage acute lymphoblastic leukemia; B-CLL—B-cell chronic lymphocytic leukemia; BCL2/MYC—BCL2/MYC-rearranged; BL—Burkitt lymphoma; CHL—classic Hodgkin lymphoma; CML—chronic myeloid leukemia; CRLF2—CRLF2 (non-Ph-like); CTCL—cutaneous T-cell lymphoma; DLBCL—diffuse large B-cell lymphoma; DUX4—DUX4-rearranged; ENKTL—extranodal NK/T-cell lymphoma; FL—follicular lymphoma; HCL—hairy cell leukemia; HLF—TCF3/TCF4-HLF; HSTCL—hepatosplenic T-cell lymphoma; iAMP21—intrachromosomal amplification of chromosome 21; IKZF1 N159Y—IKZF1 missense alteration encoding p.Asn159Tyr; JMML—juvenile myelomonocytic leukemia; KMT2A—KMT2A-rearranged; MALT—extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue; MCL—mantle cell lymphoma; MEF2D—MEF2D-rearranged; MM—multiple myeloma; MZL—marginal zone lymphoma; n—number of cases; NLPHL—nodular lymphocyte predominant Hodgkin lymphoma; NUTM1—NUTM1-rearranged; PAX5alt—PAX5 alterations; PAX5 P80R—PAX5 p.Pro80Arg (P80R) alteration; Ph—Philadelphia chromosome (BCR-ABL1); PTCL—peripheral T-cell lymphoma, not otherwise specified; T-ALL—T-cell lineage acute lymphoblastic leukemia; ZNF384—ZNF384-rearranged. Dots depict outliers. p-values of (D) Mann–Whitney U test and (A–C) Kruskal–Wallis test are shown.